Core Viewpoint - Fagron has received Brazilian antitrust clearance for the acquisitions of Purifarma and Injeplast, marking a significant advancement in its M&A strategy in Latin America [1][2]. Group 1: Acquisitions and Strategic Importance - The acquisitions of Purifarma and Injeplast will enhance Fagron's portfolio and capabilities in Brazil, aligning with the company's long-term growth objectives [2]. - Purifarma's large-scale operations in Essentials present substantial potential for profitability improvements within 18 months post-closing through product portfolio expansion and operational efficiencies [3]. - Injeplast will enhance Fagron's vertical integration by providing high-quality packaging solutions, thereby broadening the product portfolio and customer base in Latin America and other regions [4]. Group 2: Management Commentary - CEO Rafael Padilla emphasized that the approvals from CADE facilitate the closing of the acquisitions, reinforcing Fagron's leadership in Brazil and supporting its strategy of combining targeted M&A with operational excellence while maintaining financial discipline [5]. Group 3: Company Overview - Fagron is a leading global company in pharmaceutical compounding, delivering personalized medicine across more than 35 countries [6]. - The company is based in Nazareth, Belgium, and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [7].

Core Viewpoint - Fagron has announced the acquisition of University Compounding Pharmacy (UCP) in North America, which will enhance its presence in the pharmaceutical compounding market, particularly in the health and wellness segment [1][3][4]. Group 1: Acquisition Details - The enterprise value of the acquisition is approximately $41.5 million, fully financed through Fagron's own resources, and is subject to customary clearance [5]. - UCP specializes in hormones and urology, and has a strong compliance record, making it a complementary addition to Fagron's existing operations [3][4]. - The acquisition is expected to generate around $25 million in annual revenue, with an EBITDA margin below Fagron's existing group margin, and synergies are anticipated over the next 18–24 months [5]. Group 2: FDA Inspection Update - Fagron's facilities in Wichita and Las Vegas were inspected by the FDA, with no repeated observations from the 2024 inspection in Wichita, indicating successful remediation of prior concerns [2][6]. - Following a new routine inspection, the FDA issued a Form 483 with six observations for Fagron Sterile Services and four observations for the 503B Anazao Health facility in Las Vegas [7]. - The company is committed to addressing the FDA's inspectional observations and is implementing corrective actions to enhance its protocols [8].

Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 31 July 2025 – 7:00 AM CET Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025 We also wish to thank Els Vandecandelaere, who will be stepping down from the Board. Her guidance and commitment have been instrumental in Fagron's development into a leader in personalized medicine. Looking ahead, we remain confident in our outlook and are reiterating both our FY 2025 and mid- ...

Group 1 - Fagron has issued 85,000 new shares as a result of the exercise of subscription rights on June 6, 2025 [1] - The total share capital of Fagron currently amounts to €504,303,905.59, with a total of 73,313,904 shares with voting rights [2] - There are 1,465,833 rights to subscribe to not yet issued shares with voting rights [2] Group 2 - Fagron is a leading global company in pharmaceutical compounding, providing personalized medicine to various healthcare facilities in 35 countries [3] - The company is registered in Nazareth and listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [4] - Fagron's operational activities are managed by its Dutch subsidiary, Fagron BV, headquartered in Rotterdam [4]

Group 1 - Fagron held its annual general shareholders meeting where all voting items were approved [1] - The meeting approved Fagron's annual financial statements and a dividend proposal of €0.35 per share for the fiscal year 2024 [2] - The remuneration policy and the appointment of the statutory auditor for the financial years 2025 to 2027 were also approved [2] Group 2 - Ann Desender BV was reappointed as independent non-executive director until the annual general meeting of 2029 [2] - All meeting documents are available on Fagron's website, including the minutes of the meetings [3] - Fagron operates in over 30 countries, focusing on personalized medicine for hospitals, pharmacies, clinics, and patients [4] Group 3 - Fagron NV is registered in Nazareth and listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [5] - The operational activities are managed by Fagron BV, headquartered in Rotterdam [5] Group 4 - The dividend calendar includes an ex-dividend date of 19 May 2025, record date of 20 May 2025, and payment date of 21 May 2025 [7]